Abstract
The natural product hymenialdisine was first isolated in 1980 from the marine sponges of the genera Hymeniacidon, Acanthella, Axinella and Pseudaxinyssa. The structure was elucidated on the basis of X-ray crystallography demonstrating a structurally interesting pyrrole-azepin-8-one ring system bonded to a glycocyamidine ring. Great interest has been taken in synthesizing this type of scaffold due to its potent activity in competitive kinase inhibition. In addition, several patents have claimed pharmacological use of these compounds for prevention and treatment of different diseases. The challenging syntheses of hymenialdisine and its analogues are described in this review as well as their evaluation as kinase inhibitors.
Keywords: Natural products, marine sponge metabolites, hymenialdisine, kinase inhibitors, chemotherapy
Current Medicinal Chemistry
Title: Preparation of Hymenialdisine, Analogues and Their Evaluation as Kinase Inhibitors
Volume: 16 Issue: 24
Author(s): T. N.T. Nguyen and J. J. Tepe
Affiliation:
Keywords: Natural products, marine sponge metabolites, hymenialdisine, kinase inhibitors, chemotherapy
Abstract: The natural product hymenialdisine was first isolated in 1980 from the marine sponges of the genera Hymeniacidon, Acanthella, Axinella and Pseudaxinyssa. The structure was elucidated on the basis of X-ray crystallography demonstrating a structurally interesting pyrrole-azepin-8-one ring system bonded to a glycocyamidine ring. Great interest has been taken in synthesizing this type of scaffold due to its potent activity in competitive kinase inhibition. In addition, several patents have claimed pharmacological use of these compounds for prevention and treatment of different diseases. The challenging syntheses of hymenialdisine and its analogues are described in this review as well as their evaluation as kinase inhibitors.
Export Options
About this article
Cite this article as:
Nguyen N.T. T. and Tepe J. J., Preparation of Hymenialdisine, Analogues and Their Evaluation as Kinase Inhibitors, Current Medicinal Chemistry 2009; 16 (24) . https://dx.doi.org/10.2174/092986709788803015
DOI https://dx.doi.org/10.2174/092986709788803015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets Proteomic Classification of Breast Cancer
Current Drug Targets Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Recent Patents on MicroRNA-Induced Pluripotent Stem Cell Generation
Recent Patents on Regenerative Medicine The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Adenoviral Vectors for Cancer Gene Therapy
Current Genomics Apoptosis in Sepsis: Mechanisms, Clinical Impact and Potential Therapeutic Targets
Current Pharmaceutical Design DNA Methylation in Colon Cancer: Challenges and Opportunities
Epigenetic Diagnosis & Therapy (Discontinued) Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Recent Patents Relating to Tumor Suppressor Genes
Recent Patents on DNA & Gene Sequences Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review
Current Medicinal Chemistry MicroRNA Regulation of Embryonic Stem Cell Pluripotency and Differentiation
Current Stem Cell Research & Therapy Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine